reduce basal insulin when starting glp-1 receptor agonist Combination of and agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes? | Diabetology & Metabolic Syndrome Current Insights, Advantages and Challenges
Description
Glucose Control's evidence rests largely on a single proof-of-concept 2020 clinical trial published in BMJ Open Diabetes Research & Care
And because the program is open to anyone, its flexible, scalable, and simple to integrate
Forest plot of GLP-1 receptor agonists versus comparators on the risk of pneumonia
GLP-1 can control the secretion of various neurotransmitters, the progression of neuroinflammation, and the increase in insulin sensitivity in the brain (Athauda and Foltynie, 2016)
